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SUMMARY – Chronic obstructive pulmonary disease (COPD) is a progressive pulmonary di-
sease characterized by systemic inflammation. The aim of this study was to correlate the parameters 
of systemic inflammation, C-reactive protein (CPR) and total leukocyte count, with clinical indica-
tors of the disease. Our study included 157 COPD patients, both outpatients and those hospitalized 
at the Knez Selo Department of Pulmonology of the Niš Clinical Centre during a six-month period, 
while in the phase of disease exacerbation. The symptoms of COPD in each patient were estimated 
by the COPD Assessment Test (CAT) and modified Medical Research Council (mMRC) dyspnea 
scale. The parameters of pulmonary function (FEV1 and FVC), acid-base status, body mass index, 
history of exacerbation and comorbidities were also evaluated. The level of CRP, but not leukocytes, 
showed significant correlation with the severity of clinical presentation according to GOLD classifi-
cation. The higher the CRP concentration, the higher was the disease severity determined according 
to GOLD classification (p<0.001). There was no statistically significant difference in CRP level and 
leukocyte count according to comorbidities (p=0.29). The level of CRP was higher in patients with 
a high CAT score and mMRC scale (p<0.001). The same trend was observed for leukocyte count 
when compared with CAT results, but not when correlated to mMRC scale. The level of CRP du-
ring COPD exacerbation can be an independent predictor of the disease severity and paraclinical 
findings. 
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Introduction
Chronic obstructive pulmonary disease (COPD) 
is a common and treatable disease characterized by 
persistent airflow limitation that is usually progressive 
and associated with an enhanced chronic inflammato-
ry response in the airways and the lung to noxious par-
ticles or gases. Exacerbations and comorbidities con-
tribute to the overall severity in individual patients1,2. 
COPD is currently the fourth leading cause of death 
and a considerable economic and social burden world-
wide, especially in underdeveloped countries3-6.
Diagnostic and therapeutic parameters used to 
evaluate COPD are based on assessment of symp-
toms, severity of airflow limitation, history of exacer-
bations, and comorbidities2. The COPD Assessment 
Test (CAT) is a short, easy-to-complete health status 
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tool that has been developed to help patients and their 
clinicians assess and quantify the symptoms and im-
pacts of COPD7,8. On the other hand, a weak breath 
is the most common symptom reported by long-term 
COPD patients9, and it significantly reduces the qual-
ity of life10,11. Therefore, it is necessary to estimate pa-
tients’ airflow and thus modified Medical Research 
Council (mMRC) dyspnea scale is used12. It is simple 
to use with a predictive value and it correlates with 
clinical and functional pulmonary parameters13-15. 
Numerous studies have confirmed that acute ex-
acerbations of COPD imply increased levels of C-re-
active protein (CRP), as well as modification of other 
inflammatory parameters16-18.
The aim of this study was to correlate the inflam-
mation parameters of CRP and leukocyte count with 
clinical indicators of COPD (disease symptoms as-
sessed by CAT and mMRC dyspnea scale, history of 
exacerbation and comorbidities, and blood gas analy-
sis results). To our knowledge, no similar study has 
been conducted in Serbia and Montenegro to date.
Patients and Methods
This prospective study was conducted in the Niš 
Clinical Centre and was approved by the institution 
Ethics Committee. Before taking part in the research, 
a written consent was obtained from each patient. 
The research included 157 patients (115 men and 45 
women) suffering from COPD, both outpatients and 
those hospitalized at the Knez Selo Department fo 
Pulmonology of the Niš Clinical Centre during a six-
month period (from November to May 2013). Patients 
diagnosed with bronchial asthma, pneumonia and 
decompensated cardiomyopathy were excluded, as 
well as those who had suffered myocardial infarction 
in the last 6 weeks. Patients included in the study were 
experiencing an exacerbation of the disease. 
The diagnosis of COPD was made based on 
GOLD guidelines2. Inclusion criteria were postbron-
chodilation test ratio of the forced expiratory volume 
in the first second (FEV1) and the forced vital capac-
ity (FVC) below 70%. The questionnaire used for es-
timation of COPD-CAT and mMRC dyspnea scale, 
as well as spirometric parameters were obtained dur-
ing first outpatient or hospital treatment. The ques-
tionnaires were translated and back translated into 
Montenegrin language. All patients filled them in 
by themselves. Doctors did assist patients but did not 
suggest any answer. 
Blood analysis was done in all patients. Spiromet-
ric parameters, FEV1 and FVC, were obtained using 
Table 1. General and demographic characteristics of patients
Variable  N %
Gender Male/Female 115/42 73.2/26.8
Smoking habit Non smokers 25 15,9
 Smokers 68 43,3
 Ex smokers 64 40,8
Exacerbations Rare/Frequent 42/115 26.8/73.2
Age  67.76±9.39 68.00 (41.00-89.00)
BMI  26.61±6.28 25.88 (15.59-57.48)
FEV1  1.26±0.54 1.13 (0.33-2.87)
FEV1%  47.08±14.93 45.50 (16.60-79.90)
FVC  2.34±0.88 2.25 (0.68-5.03)
FVC%  69.38±17.80 67.50(28.90-105.80)
CRP  25.09±29.72 11.60 (1.20-110.00)
Leukocyte count  9.06±3.08 8.30 (3.50-18.60)
BMI = body mass index; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; 
FEV1% = FEV1/FVC ratio; FVC% = percent predicted forced vital capacity; CRP = C-reactive 
protein
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the Erich Jaeger Masterlab (Germany) spirometric 
apparatus. Electrocardiography, chest radiography, 
information on the disease duration, comorbidities 
and exacerbations in previous year were obtained from 
the patients. 
Statistics
Demographic variables (i.e. gender, age and smok-
ing status) as well as clinical determinants were sum-
marized in order to characterize the study popula-
tion. Statistical analysis included descriptive statistics, 
Kolmogorov-Smirnov test, t-test, ANOVA, Kruskal 
Wallis test and regression analysis. The value of p less 
than 0.05 was considered statistically significant. The 
SPSS version 16.0 statistical program was used on 
data analysis.
Results
Table 1 summarizes demographic and clini-
cal characteristics of study patients. The study was 
performed on 157 patients, mainly male (n=115) 
and smokers (n=68), mean age 67.76±9.39. Patients 
with a more severe form of COPD, i.e. those with a 
higher class of disease severity according to GOLD, 
had much more frequent exacerbations, higher CAT 
score and higher mMRC dyspnea score (p<0.001). 
CRP showed significant correlation with the severi-
ty of clinical presentation. The higher the CRP level, 
the higher was the class of disease severity accord-
ing to GOLD (p=0.005). These data are presented 
in Table 2.
Post hoc analysis determined that patients without 
comorbidities had a statistically significantly lower 
body mass index (BMI) in comparison to both pa-
tients with two or less comorbidities and patients with 
three or more comorbidities (p=0.01 both). There was 
no statistically significant difference in CRP level and 
leukocyte count according to comorbidities. The val-
ues of FEV1 (L), FVC (L) and FVC (%) decreased 
statistically significantly with the increase of comor-
bidities (p=0.028, p=0.002 and p=0.005, respectively). 
These results are shown in Table 3.
Patients with a high CAT score had statisti-
cally more frequent exacerbations (p<0.001). BMI 
was statistically significantly lower in patients with 
a high CAT score (p=0.02). CRP value was statis-
tically significantly higher in patients with a high 
CAT score (p<0.001). Leukocyte count was statis-
tically significantly higher in patients with a high 
CAT score (p=0.002). These results are summarized 
in Table 4.
Patients with a high CAT score had significant-
ly lower values of FEV1 (L), FEV1%, FVC (L) and 
FVC% (p<0.001 all), and lower values of partial oxy-
gen pressure (pO2; p=0.016), bicarbonate (HCO3; 
p=0.025) and oxygen saturation (sO2; p=0.023). The 
values of partial carbon dioxide pressure (pCO2) in 
arterial blood were statistically significantly higher in 
patients with a high CAT score (p=0.014) (Table 5).
Table 2. Patient characteristics in relation to GOLD classification
 
GOLD 2 GOLD 3 GOLD 4
p
n=60 n=79 n=18
Age (yrs) 67.67±9.49 68.29±9.85 65.78±6.84 0.592
Gender (M/F) 43/17 58/21 23.66+/-5.33 0.875
BMI 28.18±7.17 26.08±5.43 23.66±5.33 0.015
Exacerbation 1.55±1.57 5.44±2.62 9.83±1.69 <0.001
FEV1 1.75±0.52 1.02±0.25 0.67±0.12 <0.001a
CAT 17.98±6.37 27.94±6.34 34.89±2.76 <0.001b
mMRC 1.33±0.71 2.52±0.90 3.67±0.48 <0.001b
CRP 9.34±14.14 26.74±32.66 38.79±27.78 0.006b
Leukocyte count 8.99±3.64 8.67±2.76 10.38±3.18 0.264b
aANOVA; bKruskal-Wallis test; BMI = body mass index; FEV1 = forced expiratory volume in 1 
second; CAT = COPD Assessment Test; mMRC = modified Medical Research Council scale; CRP 
= C-reactive protein
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Patients with a high mMRC score had statistically 
more frequent exacerbations (p<0.001). CRP was sta-
tistically significantly higher in patients with a high 
mMRC score (p<0.001). This trend was not observed 
for leukocyte count according to mMRC scale. These 
data are shown in Table 6.
Patients with a high mMRC score had statisti-
cally significantly lower values of FEV1 (L), FEV1%, 





comorbidities ≤2 3 or more
n=32 n=104 n=21
Age (yrs) 64.03±11.06 67.81±8.99 73.24±5.29 0.002
Gender (M/F) 3.57 72/32 6.00 0.209
BMI 23.78±3.62 27.08±7.04 28.59±3.86 0.010
Smoking habit  
Non smokers 4 (12.5) 17 (16.3) 4 (19.0)
0.818Smokers 16 (50.0) 42 (40.4) 10 (47.6)
Ex smokers 12 (37.5) 45 (43.3) 7 (33.3)
FEV1 1.46±0.56 1.23±0.55 1.07±0.40 0.028
FVC 2.76±0.79 2.30±0.90 1.93±0.64 0.002
FVC% 75.83±15.94 69.32±18.26 59.85±14.07 0.005
CRP 26.68±30.17 20.52±25.31 40.38±40.51 0.266
Leukocyte count 9.92±2.81 8.44±2.38 10.57±4.76 0.291
BMI = body mass index; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; FVC% = percent predicted forced 
vital capacity; CRP = C-reactive protein
Table 4. Demographic characteristics of patients in relation to COPD Assessment Test (CAT) values
  
High CAT Low CAT
 p
n=79 n=78
Age (yrs)  69.15±8.77 66.36±9.85 1.876 0.063
Gender (M/F)  60/19 55/23 0.347 0.556
Smoking habit Non smoking 11 14  
0.745 Smokers 36 32  
 Ex smokers 32 32  
Exacerbations Rare 1 41 50.123
<0.001
 Frequent 78 37  
BMI  25.44±4.79 27.78±7.32 2.355 0.020
CRP  37.11±32.09 5.75±6.99 4.380 <0.001
Leukocyte count  9.97±3.23 7.66±2.25 3.149 0.002
BMI = body mass index; CRP = C-reactive protein
FVC (L) and FVC% (p<0.001 all), and lower values 
of HCO3 in arterial blood (p=0.002). The values of 
pCO2 in arterial blood were statistically signifi-
cantly higher in patients with a high mMRC score 
(p=0.019).
There was a statistically significant correla-
tion between CAT score and mMRC dyspnea scale 
(rho=0.963, p<0.001) (Fig. 1).
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Discussion
Our research showed the CRP value to correlate 
with the severity of the COPD clinical presentation. 
These results are in favor of the proven fact that COPD 
is a systemic inflammatory disease which primarily af-
fects the lungs17-20. Similar results were obtained in the 
studies which suggest that the reduced lung function 
in COPD is associated with increased levels of sys-
temic inflammatory markers20-24. Although leukocyte 
Table 5. Values  of examined parameters compared to 
COPD Assessment Test (CAT) score
 
High CAT Low CAT
 p
n=79 n=78
FEV1 0.95±0.29 1.57±0.57 8.533 <0.001
FEV1% 37.59±10.33 56.70±12.54 10.409 <0.001
FVC 1.95±0.60 2.74±0.94 6.277 <0.001
FVC% 60.02±15.13 78.87±15.13 7.806 <0.001
pH 7.42±0.06 7.43± 0.872 0.386
pO2 57.72±10.72 63.77±9.03 2.504 0.016
pCO2 45.63±13.65 40.14±5.29 2.527 0.014
HCO3 28.16±4.27 26.06±3.16 2.355 0.025
sO2 88.02±8.48 91.54±4.65 2.319 0.023
FEV1 = forced expiratory volume in 1 second; FVC = forced vital 
capacity; FEV1% = FEV1/FVC ratio; FVC% = percent predicted 
forced vital capacity;  pCO2 = partial carbon dioxide pressure; 
HCO3 = bicarbonate; sO2 = oxygen saturation
Table  6. Demographic characteristics of patients in relation to modified Medical Research 
Council (mMRC) scale values
  
High mMRC Low mMRC
 p
n=108 n=49
Age (yrs)  68.82±9.25 65.43±9.38 2.111 0.093
Gender (M/F)  79/29 36/13 0.002 0.966
Smoking habit Non smokers 16 9  
0.211 Smokers 43 25  
 Ex smokers 49 15  
Exacerbations Rare 4 38 90.078
<0.001
 Frequent 104 11  
BMI  26.26±6.12 27.36±6.62 1.203 0.229
CRP  30.87±31.51 6.10±8.05 3.120 0.002
Leukocyte count  9.41±3.17 7.96±2.57 1.756 0.079
BMI = body mass index; CRP = C-reactive protein
count is considered as a marker of systemic inflamma-
tion in COPD25, in our study leukocyte count did not 
show any significant correlation with the severity of 
COPD. Several studies showed that leukocyte count 
was sometimes poor predictor of mortality in COPD 
patients25. 
In the present study, no statistically significant 
correlation was found between the level of CRP and 
leukocyte count  and comorbidities. This result could 
be of great importance because it might suggest that 
CRP and leukocyte count are independent predic-
tors of systemic inflammation and are not related to 
co-occurring diseases. Inflammatory response at the 
Fig. 1. Correlation between COPD Assessment Test 
(CAT) score and values of modified Medical Research 
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lung level to noxious agents causes systemic inflam-
matory changes and results in significant extrapul-
monary effects that contribute to the increase of CRP 
and leukocyte count2. In support of this interpreta-
tion, some research results indicate a higher rate of 
association of COPD with nutritional abnormalities, 
skeletal muscle dysfunction and an increased risk of 
diseases such as cardiovascular, metabolic, neurolog-
ical and other diseases26,27. Lower CAT scores were 
associated with lower values  of CRP and leukocyte 
count, which supports the previously reported re-
sults28. Given the fact that lower  CAT scores are as-
sociated with better spirometry and blood gas analy-
sis results16-18,29, lower values  of CRP and leukocyte 
count indicate better clinical profile of COPD, as 
also shown in our study.
Lower values of the mMRCA dyspnea scale are 
associated with lower CRP and leukocyte count. 
The results of our study indicated that this type of 
relationship could only be applied to CRP level, but 
not to leukocyte count. These results are consistent 
with previously reported results30-32. Lower values  of 
the mMRC dyspnea scale are associated with better 
spirometry and blood gas analysis results in COPD. 
Thus, we can conclude that lower values  of CRP cor-
relate better with clinical findings in these patients. 
Some results of our study indicate that the value of 
CRP should be analyzed during acute exacerba-
tion of COPD in order to assess the degree of sys-
temic inflammation, as suggested from several other 
researches17,18,29. 
We also found significant correlation between 
CAT and mMRC dyspnea scale. Similar results have 
been reported from other studies28,33. 
The mMRC dyspnea scale and CAT provide com-
prehensive assessment of the overall impact of the 
disease on the quality of life in COPD patients. In 
clinical setting, it is useful to use some other param-
eters to assess the severity of COPD. In addition to 
lung function, which is an essential component for 
the diagnosis and defining the severity of COPD, the 
frequency of exacerbations, comorbidities, blood gas 
analysis, blood inflammatory markers (CRP and leu-
kocyte count) should also be taken in consideration. 
The CRP level in COPD exacerbation may be 
an independent predictor of the severity and clinical 
findings in these patients.
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Sažetak
KORELACIJA IZMEĐU C-REAKTIVNOG PROTEINA I STUPNJA TEŽINE KOPB  
N. Milačić, B. Milačić, M. Milojković, S. Ljubisavljević, S. Vodopić, M. Hasanbegović i M. Đurovic
Kronična opstruktivna plućna bolest (KOPB) je progresivna upalna bolest pluća obilježena sistemskom upalom. Cilj 
ovoga istraživanja bio je utvrditi korelaciju između parametara sistemske upale, tj. C-reaktivnog proteina (CRP) i ukupnog 
broja leukocita s kliničkim i parakliničkim pokazateljima bolesti. U istraživanje je bilo uključeno 157 bolesnika s KOPB 
koji su ambulantno i bolnički liječeni na Klinici za plućne bolesti Knez Selo Kliničkog centra Niš u razdoblju od šest mje-
seci, i to tijekom faze pogoršanja KOPB. Kod svakog bolesnika simptomi KOPB su se procjenjivali pomoću testa COPD 
Assessment Test (CAT) i ljestvice mMRC-dispneja. Uz to, procjenjivali su se parametri plućne funkcije (FEV1 i FVC), kao 
i acidobazni status, indeks tjelesne mase, povijest pogoršanja i komorbiditeti. Razina CRP, ali ne i leukociti, pokazala je 
značajnu korelaciju s težinom kliničke prezentacije prema klasifikaciji GOLD. Viša razina CRP nađena je kod bolesnika 
s višom klasom prema klasifikaciji GOLD, odnosno kod bolesnika s težim oblikom bolesti (niži FEV1) u egzacerbaciji 
(p<0,001). Nije bilo statistički značajne razlike u razini CRP i broju leukocita u odnosu na komorbiditete (p=0,29). Ra-
zina CRP je bila viša u bolesnika s visokim zbirom CAT i ljestvicom mMRC-dispneja (p<0,001). Korelacijska analiza je 
pokazala povezanost između razine CRP i ljestvice mMRC-dispneja, ali je ta korelacija izostala između razine leukocita i 
vrijednosti ljestvice mMRC-dispneja. Zaključuje se kako razina CRP tijekom faze pogoršanja KOPB može biti neovisni 
prediktor težine bolesti, ali i pokazatelj parakliničkih karakteristika kod ovih bolesnika. 
Ključne riječi: Plućna bolest; Kronična opstruktivna plućna bolest – dijagnostika; Kronična opstruktivna plućna bolest – kla-
sifikacija; C-reaktivni protein; Respiratorni funkcionalni testovi; Stupanj težine bolesti, određivanje; Ankete i upitnici
